Monsanto the disposition of product lines unrelated to agriculture. In 1985, Monsanto acquired G. D. Searle & Company, a life sciences company that focused on pharmaceuticals, agriculture and animal health. In 1993, its Searle division filed a patent application for Celebrex, which in 1998 became the first selective COX‑2 inhibitor to be approved by the U.S. Food and Drug Administration (FDA). Celebrex became a blockbuster drug and was often mentioned as a key reason for Pfizer's acquisition of Monsanto's pharmaceutical business in 2002. In 1994, Monsanto introduced a recombinant version of bovine somatotropin, brand-named Posilac. Monsanto later sold this business to
Monsanto It found "an urgent need to reshape the terms of the debate about GM in Europe". EuropaBio proposed the recruitment of high-profile "ambassadors" to lobby EU officials. In September 2017 Monsanto lobbyists were banned from the European parliament after the Monsanto refused to attend a parliamentary hearing into allegations of regulatory interference. After the 2010 Haiti earthquake, Monsanto donated $255,000 for disaster relief and 60,000 seed sacks (475 tons) of hybrid (non-GM) corn and vegetable seeds worth $4 million. However, a Catholic Relief Services (CRS) rapid assessment of seed supply and demand for the five most common food security crops